Meeting
2024 ASCO Genitourinary Cancers Symposium
Safety, tolerability, and dosimetry of 177Lu-TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer (ProstAct-SELECT).
Authors
Nat Lenzo
Genesiscare, East Fremantle, Australia
Nat Lenzo , Ken O'Byrne , Stanley Ngai , Danielle Meyrick , Neel Patel , Colin Hayward
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04786847
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS253)
DOI
10.1200/JCO.2024.42.4_suppl.TPS253
Abstract #
TPS253
Poster Bd #
Q14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.
First Author: William Kevin Kelly
Poster
2022 ASCO Annual Meeting
177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT).
First Author: Paola Antonini
Poster
2024 ASCO Genitourinary Cancers Symposium
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
First Author: Charlotte Hawkins
Poster
2023 ASCO Genitourinary Cancers Symposium
Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Niven Mehra